These two companies have performed better than most recently.
News & Analysis: Exelixis
Investors are excited about the biotech's positive news from a key late-stage clinical study.
Investors were none too happy with the cancer specialist's Q3 results last month.
A slowdown in the biotech’s main franchise shouldn’t have come as a surprise.
A third-quarter earnings surprise and a European approval gave the stock some lift.
A third-quarter earnings beat suggests Exelixis really can compete with big pharma.
The company hopped over investors' wall of worry.
The company announced a disappointing clinical trial failure, which fortunately wasn't for its top-selling drug.
Exelixis' shares continue to revert to the mean. Is the bottom near?
Slowing growth has investors worried.
A 104% gain last year wouldn't have been possible without lead drug Cabometyx.